Efficacy of peripheral kappa agonist fedotozine versus placebo in treatment of irritable bowel syndrome. A multicenter dose-response study.
about
Novel pharmacology: asimadoline, a kappa-opioid agonist, and visceral sensationEfficacy of on-demand asimadoline, a peripheral kappa-opioid agonist, in females with irritable bowel syndromeThe Useage of Opioids and their Adverse Effects in Gastrointestinal Practice: A ReviewNovel developments with selective, non-peptidic kappa-opioid receptor agonistsFunctional GI disorders: from animal models to drug development.Effects of a kappa-opioid agonist, asimadoline, on satiation and GI motor and sensory functions in humans.Review article: the treatment of functional abdominal bloating and distension.Review article: clinical evidence to support current therapies of irritable bowel syndrome.Treatment of irritable bowel syndrome: a review of randomised controlled trials.Emerging treatments for irritable bowel syndrome.Peripheral opioids for functional GI disease: a reappraisal.Guideline for opioid therapy and chronic noncancer pain.Pharmacotherapy: non-serotonergic mechanisms.Centrally acting agents and visceral sensitivity.Clinical perspectives, mechanisms, diagnosis and management of irritable bowel syndrome.Review article: bloating in functional bowel disorders.The role of experimental models in developing new treatments for irritable bowel syndrome.Evidence-based clinical practice guidelines for irritable bowel syndrome.Peripheral kappa-opioid agonists for visceral pain.Efficacy and safety of the peripheral kappa agonist fedotozine versus placebo in the treatment of functional dyspepsia.Emerging drugs for irritable bowel syndrome.Drugs affecting visceral sensitivity: ready for the prime time?Systematic review: the efficacy of treatments for irritable bowel syndrome--a European perspective.Systematic review: the safety and tolerability of pharmacological agents for treatment of irritable bowel syndrome--a European perspective.Drug development for the irritable bowel syndrome: current challenges and future perspectivesSerotonergic and non-serotonergic targets in the pharmacotherapy of visceral hypersensitivity.Visceral analgesics: drugs with a great potential in functional disorders?Alverine citrate fails to relieve the symptoms of irritable bowel syndrome: results of a double-blind, randomized, placebo-controlled trial.Human native kappa opioid receptor functions not predicted by recombinant receptors: Implications for drug designFedotozine, a kappa-opioid agonist, prevents spinal and supra-spinal Fos expression induced by a noxious visceral stimulus in the rat.New and emerging treatments for irritable bowel syndrome and functional dyspepsia.Réfutation : Les nouvelles recommandations sur les opioïdes nuiront-elles plus qu’elles aideront les gens? Non.Rebuttal: Will the new opioid guidelines harm more people than they help? No.Towards an Effective Peripheral Visceral Analgesic: Responding to the National Opioid Crisis.
P2860
Q24644669-6A5387C3-5254-411C-B863-228415CF3D89Q24684839-BCC3EB01-0455-4E11-8A28-37CC11A175B5Q26851158-2468D976-B3CF-4042-8F1A-0E0611629551Q28259198-8EACF33B-FF9F-4E5B-B873-C1BD9A260374Q30433078-1FF6879E-332E-422C-BDF6-0E7E9692CA10Q33426587-9C5AE68D-AB85-44ED-A534-D018DA074A9DQ33450132-62D2BD4D-51C5-44F3-A64A-0B7C2454720FQ33701278-5092242C-AA0F-4569-8789-1AB8B92448B6Q34130605-77371968-0FBD-49ED-83BC-EC783166B4B3Q34482014-7E5F1DAF-0658-4F0C-B734-D248B7704DD9Q34525733-A92B6364-1466-48DE-A469-6A33805F7883Q34556388-39FE5CEB-5C28-4CB8-9FD5-F9DA591FC535Q34699864-B566BBE6-F37C-4895-A5F6-F5480D280E9FQ34699870-0192D6DE-8678-47AF-92A2-21406A9B9F31Q34786704-FD885F26-02F2-4720-8D71-5522E09E9BA3Q34975845-9D55E282-F83B-49BA-8F21-D1F7758197FFQ35071310-82E4E05D-E2F1-4465-9C87-DBE4743BE9F1Q35513973-27C82B63-3534-4FF0-B090-68AA27EFCDDBQ35722680-C369EEB6-CE25-40C6-BD59-7C1F536C15A1Q35841225-F6403EF2-49B5-451C-9DDD-5DF78CEFF678Q36458417-277F5D44-3624-4999-B29A-1966F2307778Q36478102-167739CF-8DC7-4916-8433-8D2987EFC8AFQ36536707-42858519-CA6D-41E4-9B94-60AEB6F5F934Q36536709-EB5FFEB0-5262-4C6C-91CC-6024C16167E7Q36579818-8236077D-C28A-472E-BA52-AD948C179F44Q36728938-97E8067A-CD5A-40A0-93FC-165C2427FE26Q37118821-3AB5A692-A282-4591-9F65-561CACCD32E5Q39406612-505B1F7F-E147-4957-83DD-798EB7449BE5Q39522869-7D22E77D-B331-4B44-922B-17A269454E7CQ44331209-0D938AC4-660A-4019-9D2E-A3B7BF573297Q46576618-44204355-5BB2-4009-ABDC-CD282FECD247Q49961236-1BECDCDD-B9A0-409B-9DD9-3220C6D43F4AQ49961255-BD5F99FE-4F55-4923-B6B7-A0A60AAA0A82Q52315691-14610521-FA16-47A8-8A28-FE1A98A6316C
P2860
Efficacy of peripheral kappa agonist fedotozine versus placebo in treatment of irritable bowel syndrome. A multicenter dose-response study.
description
1995 nî lūn-bûn
@nan
1995年の論文
@ja
1995年論文
@yue
1995年論文
@zh-hant
1995年論文
@zh-hk
1995年論文
@zh-mo
1995年論文
@zh-tw
1995年论文
@wuu
1995年论文
@zh
1995年论文
@zh-cn
name
Efficacy of peripheral kappa a ...... lticenter dose-response study.
@en
type
label
Efficacy of peripheral kappa a ...... lticenter dose-response study.
@en
prefLabel
Efficacy of peripheral kappa a ...... lticenter dose-response study.
@en
P2093
P356
P1476
Efficacy of peripheral kappa a ...... lticenter dose-response study.
@en
P2093
J L Abitbol
M Dapoigny
P2888
P304
P356
10.1007/BF02209014
P577
1995-10-01T00:00:00Z
P6179
1021814042